David Hsieh, M.D.

Harold C. Simmons Comprehensive Cancer Center

Internal Medicine - Hematology/Oncology

New Patient Appointment Accepting Virtual Visits or 214-645-4673

Biography

David Hsieh, M.D., is an Assistant Professor in the Division of Hematology and Oncology at UT Southwestern Medical Center who specializes in the treatment of hepatocellular carcinoma, cholangiocarcinomas, and gall bladder cancers. Dr. Hsieh leads clinical trials to test new drugs or drug combinations in these cancers.

Dr. Hsieh earned his medical degree at the University of Arizona College of Medicine. He completed a residency in internal medicine at Mount Auburn Hospital in Cambridge, Massachusetts, and received advanced training in hematology and oncology through a fellowship at UT Southwestern.

Certified by the American Board of Internal Medicine, Dr. Hsieh joined the UT Southwestern faculty in 2019.

Dr. Hsieh's other research interests include translational studies to understand mechanisms behind the variable effectiveness of cancer therapies between patients and the development of treatment biomarkers. He also researches processes, policies, and biases in scientific research and medicine.

His awards and honors include an ASH Research Training Award and an Early Career Investigator Award from the Cancer Prevention and Research Institute of Texas.

Education & Training

Medical School - University of Arizona College of Medicine-Phoenix (2009-2013)
Residency - Mount Auburn Hospital (2013-2016), Internal Medicine
Fellowship - UT Southwestern Medical Center (2016-2019), Hematology Oncology

Honors & Awards

ASH Research Training Award for Fellows 2018
CPRIT Early Clinical Investigator Award 2020

Books & Publications

Publications
- Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation.
  Hsiehchen D, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H, Cancer cell 2024 Nov
- Landscape and Saturation Analysis of Mutations Associated With Race in Cancer Genomes by Clinical Sequencing.
  Muquith M, Hsiehchen D, The oncologist 2024 Mar 29 3 219-226
- Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.
  Muquith M, Espinoza M, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H, Hsiehchen D, Nature cancer 2024 Mar
- The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial.
  Hsiehchen D, Beg MS, Kainthla R, Lohrey J, Kazmi SM, Khosama L, Maxwell MC, Kline H, Katz C, Hassan A, Kubota N, Siglinsky E, Pillai AK, Youssoufian H, Mockbee C, Culm K, Uhlik M, Benjamin L, Brekken RA, Ahn C, Singal AG, Zhu H, Hoshida Y, Yopp AC, Nature communications 2024 Mar 15 1 2178
- Lengthy and Variable Delays in Oncology Drug Coverage Determination.
  Haque W, Rana I, Zahid S, Hsiehchen D, JAMA oncology 2023 Dec 9 12 1728-1729
- Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
  Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH, Lancet (London, England) 2023 Oct
- Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma.
  Lim M, Muquith M, Miramontes B, Espinoza M, Hsiehchen D, Cancer research communications 2023 Sep 3 9 1912-1916
- Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma.
  Alden SL, Lim M, Kao C, Shu D, Singal AG, Noonan A, Griffith P, Baretti M, Ho WJ, Kamel I, Yarchoan M, Hsiehchen D, Cancer research communications 2023 Jul 3 7 1312-1317
- Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma.
  Lim M, Muquith M, Miramontes B, Lee CJ, Espinoza M, Huang YH, Hsiehchen D, Hepatology (Baltimore, Md.) 2023 Jun
- EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma.
  Lim M, Franses JW, Imperial R, Majeed U, Tsai J, Hsiehchen D, Gastroenterology 2023 May 164 6 1006-1008.e3
- Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150.
  Espinoza M, Muquith M, Lim M, Zhu H, Singal AG, Hsiehchen D, Gastroenterology 2023 Mar
- Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding.
  Lim M, Lynch PT, Bai X, Hsiehchen D, JCO precision oncology 2023 Jan 7 e2200340
- Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.
  Hsiehchen D, Bucheit L, Yang D, Beg MS, Lim M, Lee SS, Kasi PM, Kaseb AO, Zhu H, Nature communications 2022 Dec 13 1 7477
- Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma.
  Franses JW, Lim M, Burgoyne AM, Mody K, Lennerz J, Chang J, Imperial R, Dybel SN, Dinh TM, Masannat J, Weipert CM, Hsiehchen D, The oncologist 2022 Nov 27 11 e908-e911
- Clonal hematopoiesis and differential outcomes after immune checkpoint blockade.
  Hsiehchen D, Sfreddo HJ, Zhao K, Han CY, Morris LGT, Cancer cell 2022 Oct 40 10 1071-1072
- Reversal of Hepatic Dysfunction After Exceptional Responses to Lenvatinib.
  Muquith M, Espinoza M, Hsiehchen D, Journal of gastrointestinal cancer 2022 Aug
- Adherence to a Federal Hospital Price Transparency Rule and Associated Financial and Marketplace Factors.
  Haque W, Ahmadzada M, Janumpally S, Haque E, Allahrakha H, Desai S, Hsiehchen D, JAMA 2022 06 327 21 2143-2145
- Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit.
  Dong S, Zakaria H, Hsiehchen D, The oncologist 2022 Mar 27 3 159-162
- Representation of Investigators by Gender Among Authors of Phase 3 Oncology Trials Worldwide.
  Muquith M, Pham T, Espinoza M, Hsiehchen D, JAMA network open 2022 02 5 2 e220031
- Association between immune-related adverse event timing and treatment outcomes.
  Hsiehchen D, Naqash AR, Espinoza M, Von Itzstein MS, Cortellini A, Ricciuti B, Owen DH, Laharwal M, Toi Y, Burke M, Xie Y, Gerber DE, Oncoimmunology 2022 11 1 2017162
- Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups.
  Hsiehchen D, Espinoza M, Valero C, Ahn C, Morris LGT, Journal for immunotherapy of cancer 2021 11 9 11
- Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay.
  Hsiehchen D, Espinoza M, Gerber DE, Beg MS, Cancer biology & therapy 2021 Aug 1-10
- Transparency, Accessibility, and Variability of US Hospital Price Data.
  Haque W, Ahmadzada M, Allahrakha H, Haque E, Hsiehchen D, JAMA network open 2021 May 4 5 e2110109
- Industry Payments Are Prevalent and Contagious in Subspecialty Medical Education.
  Haque W, Espinoza M, Hsiehchen D, Journal of general internal medicine 2021 Jan
- Deficiencies in the Designs and Interventions of COVID-19 Clinical Trials.
  Hsiehchen D, Espinoza M, Hsieh A, Med (New York, N.Y.) 2020 Dec 1 1 103-104
- Nonresearch Pharmaceutical Industry Payments to Oncology Physician Editors.
  Haque W, Alvarenga M, Hsiehchen D, The oncologist 2020 Jun 25 6 e986-e989
- DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden.
  Hsiehchen D, Hsieh A, Samstein RM, Lu T, Beg MS, Gerber DE, Wang T, Morris LGT, Zhu H, Cell reports. Medicine 2020 Jun 1 3
- Characteristics of Faculty Accused of Academic Sexual Misconduct in the Biomedical and Health Sciences.
  Espinoza M, Hsiehchen D, JAMA 2020 04 323 15 1503-1505
- Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors.
  Hsiehchen D, Watters MK, Lu R, Xie Y, Gerber DE, JAMA network open 2019 Sep 2 9 e1911519
- Prevalence of Female Authors in Case Reports Published in the Medical Literature.
  Hsiehchen D, Hsieh A, Espinoza M, JAMA network open 2019 May 2 5 e195000
- Nearing saturation of cancer driver gene discovery.
  Hsiehchen D, Hsieh A, Journal of human genetics 2018 Sep 63 9 941-943
- Multinational teams and diseconomies of scale in collaborative research.
  Hsiehchen D, Espinoza M, Hsieh A, Science advances 2015 Sep 1 8 e1500211

Research

Clinical trials in hepatocellular carcinoma and cholangiocarcinoma
Translational studies to identify markers of drug resistance
Discovering and advancing immunotherapies for liver cancers
Understanding mechanisms and bias in biomedical science